Dermatology News

EULAR has removed the use of systemic glucocorticoids from its recommendations for the management of psoriatic arthritis, according to a presentation at the EULAR 2023 Congress.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

Media coverage of medications may influence prescribing trends even if no new findings are reported, according to the results of a research letter published in JAMA Network Open.

The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.

A 16-month-old girl presents with a painful neck mass and fever. Her mother states that she has always had a “fullness” in the front of her neck, which suddenly increased in size.

The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.

Young adolescents with genetic skin conditions encountered worse transition readiness compared with their healthy counterparts and others with chronic conditions, according to a study.

SAN DIEGO — Internists should prioritize the assessment, documentation and treatment of wounds, according to a speaker.

In rheumatology, there is no shortage of conditions that are difficult to diagnose, with diseases like fibromyalgia and systemic lupus erythematosus sometimes taking years before being officially identified — leading to adverse outcomes.

Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.